Role of adjuvant radiotherapy after radical hysterectomy in node-negative stage IB-IIA cervical cancer with intermediate risk factors.
Identifieur interne : 004D99 ( Ncbi/Merge ); précédent : 004D98; suivant : 004E00Role of adjuvant radiotherapy after radical hysterectomy in node-negative stage IB-IIA cervical cancer with intermediate risk factors.
Auteurs : Suphet Tuipae [Thaïlande] ; Marut Yanaranop ; Noppadol OniemSource :
- Journal of the Medical Association of Thailand = Chotmaihet thangphaet [ 0125-2208 ] ; 2012.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Adénocarcinome (), Adénocarcinome (anatomopathologie), Adénocarcinome (mortalité), Adénocarcinome (radiothérapie), Carcinome épidermoïde (), Carcinome épidermoïde (anatomopathologie), Carcinome épidermoïde (mortalité), Carcinome épidermoïde (radiothérapie), Facteurs de risque, Femelle, Humains, Hystérectomie, Mâle, Radiothérapie adjuvante, Tumeurs du col de l'utérus (), Tumeurs du col de l'utérus (anatomopathologie), Tumeurs du col de l'utérus (mortalité), Tumeurs du col de l'utérus (radiothérapie).
- MESH :
- anatomopathologie : Adénocarcinome, Carcinome épidermoïde, Tumeurs du col de l'utérus.
- mortalité : Adénocarcinome, Carcinome épidermoïde, Tumeurs du col de l'utérus.
- radiothérapie : Adénocarcinome, Carcinome épidermoïde, Tumeurs du col de l'utérus.
- Adulte d'âge moyen, Adénocarcinome, Carcinome épidermoïde, Facteurs de risque, Femelle, Humains, Hystérectomie, Mâle, Radiothérapie adjuvante, Tumeurs du col de l'utérus.
English descriptors
- KwdEn :
- Adenocarcinoma (mortality), Adenocarcinoma (pathology), Adenocarcinoma (radiotherapy), Adenocarcinoma (surgery), Carcinoma, Squamous Cell (mortality), Carcinoma, Squamous Cell (pathology), Carcinoma, Squamous Cell (radiotherapy), Carcinoma, Squamous Cell (surgery), Female, Humans, Hysterectomy, Male, Middle Aged, Radiotherapy, Adjuvant, Risk Factors, Uterine Cervical Neoplasms (mortality), Uterine Cervical Neoplasms (pathology), Uterine Cervical Neoplasms (radiotherapy), Uterine Cervical Neoplasms (surgery).
- MESH :
- mortality : Adenocarcinoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms.
- pathology : Adenocarcinoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms.
- radiotherapy : Adenocarcinoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms.
- surgery : Adenocarcinoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms.
- Female, Humans, Hysterectomy, Male, Middle Aged, Radiotherapy, Adjuvant, Risk Factors.
Abstract
To assess the benefit of adjuvant radiotherapy after radical hysterectomy in node-negative FIGO stage IB-IIA cervical cancer patients with intermediate risk factors.
PubMed: 22619897
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002118
- to stream PubMed, to step Curation: 002118
- to stream PubMed, to step Checkpoint: 002118
Links to Exploration step
pubmed:22619897Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Role of adjuvant radiotherapy after radical hysterectomy in node-negative stage IB-IIA cervical cancer with intermediate risk factors.</title>
<author><name sortKey="Tuipae, Suphet" sort="Tuipae, Suphet" uniqKey="Tuipae S" first="Suphet" last="Tuipae">Suphet Tuipae</name>
<affiliation wicri:level="1"><nlm:affiliation>Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand. suphetgyn@hotmail.com</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yanaranop, Marut" sort="Yanaranop, Marut" uniqKey="Yanaranop M" first="Marut" last="Yanaranop">Marut Yanaranop</name>
</author>
<author><name sortKey="Oniem, Noppadol" sort="Oniem, Noppadol" uniqKey="Oniem N" first="Noppadol" last="Oniem">Noppadol Oniem</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22619897</idno>
<idno type="pmid">22619897</idno>
<idno type="wicri:Area/PubMed/Corpus">002118</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002118</idno>
<idno type="wicri:Area/PubMed/Curation">002118</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002118</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002118</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002118</idno>
<idno type="wicri:Area/Ncbi/Merge">004D99</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Role of adjuvant radiotherapy after radical hysterectomy in node-negative stage IB-IIA cervical cancer with intermediate risk factors.</title>
<author><name sortKey="Tuipae, Suphet" sort="Tuipae, Suphet" uniqKey="Tuipae S" first="Suphet" last="Tuipae">Suphet Tuipae</name>
<affiliation wicri:level="1"><nlm:affiliation>Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand. suphetgyn@hotmail.com</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yanaranop, Marut" sort="Yanaranop, Marut" uniqKey="Yanaranop M" first="Marut" last="Yanaranop">Marut Yanaranop</name>
</author>
<author><name sortKey="Oniem, Noppadol" sort="Oniem, Noppadol" uniqKey="Oniem N" first="Noppadol" last="Oniem">Noppadol Oniem</name>
</author>
</analytic>
<series><title level="j">Journal of the Medical Association of Thailand = Chotmaihet thangphaet</title>
<idno type="ISSN">0125-2208</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma (mortality)</term>
<term>Adenocarcinoma (pathology)</term>
<term>Adenocarcinoma (radiotherapy)</term>
<term>Adenocarcinoma (surgery)</term>
<term>Carcinoma, Squamous Cell (mortality)</term>
<term>Carcinoma, Squamous Cell (pathology)</term>
<term>Carcinoma, Squamous Cell (radiotherapy)</term>
<term>Carcinoma, Squamous Cell (surgery)</term>
<term>Female</term>
<term>Humans</term>
<term>Hysterectomy</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Radiotherapy, Adjuvant</term>
<term>Risk Factors</term>
<term>Uterine Cervical Neoplasms (mortality)</term>
<term>Uterine Cervical Neoplasms (pathology)</term>
<term>Uterine Cervical Neoplasms (radiotherapy)</term>
<term>Uterine Cervical Neoplasms (surgery)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Adénocarcinome ()</term>
<term>Adénocarcinome (anatomopathologie)</term>
<term>Adénocarcinome (mortalité)</term>
<term>Adénocarcinome (radiothérapie)</term>
<term>Carcinome épidermoïde ()</term>
<term>Carcinome épidermoïde (anatomopathologie)</term>
<term>Carcinome épidermoïde (mortalité)</term>
<term>Carcinome épidermoïde (radiothérapie)</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hystérectomie</term>
<term>Mâle</term>
<term>Radiothérapie adjuvante</term>
<term>Tumeurs du col de l'utérus ()</term>
<term>Tumeurs du col de l'utérus (anatomopathologie)</term>
<term>Tumeurs du col de l'utérus (mortalité)</term>
<term>Tumeurs du col de l'utérus (radiothérapie)</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Adénocarcinome</term>
<term>Carcinome épidermoïde</term>
<term>Tumeurs du col de l'utérus</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Adenocarcinoma</term>
<term>Carcinoma, Squamous Cell</term>
<term>Uterine Cervical Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Adénocarcinome</term>
<term>Carcinome épidermoïde</term>
<term>Tumeurs du col de l'utérus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Adenocarcinoma</term>
<term>Carcinoma, Squamous Cell</term>
<term>Uterine Cervical Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Adenocarcinoma</term>
<term>Carcinoma, Squamous Cell</term>
<term>Uterine Cervical Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Adénocarcinome</term>
<term>Carcinome épidermoïde</term>
<term>Tumeurs du col de l'utérus</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Adenocarcinoma</term>
<term>Carcinoma, Squamous Cell</term>
<term>Uterine Cervical Neoplasms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Humans</term>
<term>Hysterectomy</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Radiotherapy, Adjuvant</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Adénocarcinome</term>
<term>Carcinome épidermoïde</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hystérectomie</term>
<term>Mâle</term>
<term>Radiothérapie adjuvante</term>
<term>Tumeurs du col de l'utérus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To assess the benefit of adjuvant radiotherapy after radical hysterectomy in node-negative FIGO stage IB-IIA cervical cancer patients with intermediate risk factors.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22619897</PMID>
<DateCreated><Year>2012</Year>
<Month>05</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted><Year>2012</Year>
<Month>06</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2012</Year>
<Month>05</Month>
<Day>24</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0125-2208</ISSN>
<JournalIssue CitedMedium="Print"><Volume>95 Suppl 3</Volume>
<PubDate><Year>2012</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Journal of the Medical Association of Thailand = Chotmaihet thangphaet</Title>
<ISOAbbreviation>J Med Assoc Thai</ISOAbbreviation>
</Journal>
<ArticleTitle>Role of adjuvant radiotherapy after radical hysterectomy in node-negative stage IB-IIA cervical cancer with intermediate risk factors.</ArticleTitle>
<Pagination><MedlinePgn>S117-24</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the benefit of adjuvant radiotherapy after radical hysterectomy in node-negative FIGO stage IB-IIA cervical cancer patients with intermediate risk factors.</AbstractText>
<AbstractText Label="MATERIAL AND METHOD" NlmCategory="METHODS">Medical records of FIGO stage IB-IIA cervical cancer patients who underwent radical hysterectomy at Rajavithi Hospital between January 2000 and December 2007 with negative pelvic node were reviewed. Of the 573 node-negative stage IB-IIA cervical cancer patients, 115 had at least one of the intermediate risk factors; 18 cases received adjuvant radiotherapy (RT group) while 97 patients did not receive (non RT group). Recurrence-free survival and complications of combined treatment of each group were investigated.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The median follow-up period was 62.5 months (range 5-119 months). Of the 115 patients with any of the intermediate risk factors, 56 (48. 7%) had single intermediate risk factor and 59 (51.3%) had two or more intermediate risk factors. Sixteen patients (13.9%) developed recurrence, 6 at the locoregional site, 5 at the distant sites and 5 at synchronous sites. Eleven patients (18.6%) who had two or more intermediate risk factors developed recurrences. In the RT group, 3 patients (20.0%) developed recurrences whereas 8 patients (18.2%) in the non RT group developed recurrences (p = 0.574). The 5-year recurrence free survival rates in patients with two or more risk factors received adjuvant radiotherapy and those without adjuvant radiotherapy were 77.8% and 83.0%, respectively (p = 0.904). No locoregional recurrence occurred in patients who received adjuvant radiotherapy. Three patients had treatment related complications (2 with leg lymphedema and 1 with radiation proctitis).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Postoperative radiotherapy in node-negative stage IB-IIA cervical cancer patients with intermediate risk factors reduced only the incidence of locoregional recurrence. Distant recurrence was the major pattern of treatment failure after adjuvant radiotherapy.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tuipae</LastName>
<ForeName>Suphet</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand. suphetgyn@hotmail.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yanaranop</LastName>
<ForeName>Marut</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Oniem</LastName>
<ForeName>Noppadol</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Thailand</Country>
<MedlineTA>J Med Assoc Thai</MedlineTA>
<NlmUniqueID>7507216</NlmUniqueID>
<ISSNLinking>0125-2208</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>
<QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>
<QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007044" MajorTopicYN="Y">Hysterectomy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018714" MajorTopicYN="N">Radiotherapy, Adjuvant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>
<QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year>
<Month>5</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2012</Year>
<Month>5</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2012</Year>
<Month>6</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">22619897</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Thaïlande</li>
</country>
</list>
<tree><noCountry><name sortKey="Oniem, Noppadol" sort="Oniem, Noppadol" uniqKey="Oniem N" first="Noppadol" last="Oniem">Noppadol Oniem</name>
<name sortKey="Yanaranop, Marut" sort="Yanaranop, Marut" uniqKey="Yanaranop M" first="Marut" last="Yanaranop">Marut Yanaranop</name>
</noCountry>
<country name="Thaïlande"><noRegion><name sortKey="Tuipae, Suphet" sort="Tuipae, Suphet" uniqKey="Tuipae S" first="Suphet" last="Tuipae">Suphet Tuipae</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D99 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004D99 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:22619897 |texte= Role of adjuvant radiotherapy after radical hysterectomy in node-negative stage IB-IIA cervical cancer with intermediate risk factors. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:22619897" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |